Search
Afimetoran
go.drugbank.com/drugs/DB16580Investigational[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male
ABX1100
go.drugbank.com/drugs/DB17655InvestigationalIt was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]
Carbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedThis antibacterial is obtained from _Streptomyces halstedii_ and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains.
Gold
go.drugbank.com/drugs/DB14154InvestigationalIt is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Risvutatug rezetecan
go.drugbank.com/drugs/DB23560InvestigationalIt is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers
3-amino-5-phenylpentane
go.drugbank.com/drugs/DB02869ExperimentalThese are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalIt has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
NTLA-2002
go.drugbank.com/drugs/DB17597InvestigationalIt is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]
mRNA-3927
go.drugbank.com/drugs/DB17669InvestigationalDeveloped by Moderna Inc., it is being investigated for the treatment of propionic acidemia.[L45998]
Ofirnoflast
go.drugbank.com/drugs/DB21679InvestigationalOfirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.